Arithmetic Abilities in Children With 22q11.2DS

22q11.2 Deletion Syndrome Clinical Trial

— ARITH22  

Official title:

Study of Arithmetic Abilities of Children With 22q11.2 Deletion Syndrome Aged From 4 to 11 Years Old

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04373226
• Other study ID #: 2020-A00102-37
• Status: Recruiting
• Phase: N/A
• Start date: September 16, 2020
• Est. completion date: October 20, 2023

Study information

• Verified date: January 2022
• Source: Hôpital le Vinatier
• Contact: Caroline DEMILY, MD PH
• Phone: 0450915163
• Email: caroline.demily[@]ch-le-vinatier.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study ARITH22 will investigate the role of visuo-spatial attention on arithmetic abilities of children with 22q11.2 deletion syndrome.

Description:

Children with 22q11.2 deletion syndrome often have arithmetic learning disability because of magnitude representation impairment. Previous works suggested that magnitude representation impairment could be a result of endogenous visuo-spatial attention dysfunction in 22q11.2DS. Nevertheless this relationship is still poor explored. The influence of visuo-spatial abilities on arithmetic achievement could also be modulated by developmental age. The study ARITH22 will test these hypotheses thanks to magnitude comparisons tasks, in children with 22q11.2 deletion syndrome and matched children without developmental disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: October 20, 2023
• Est. primary completion date: July 20, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 4 Years to 11 Years

Eligibility

Inclusion Criteria:

• Diagnosis of 22q11.2 deletion syndrome or no developmental disease
• Aged from 4 to 11 years old
• French language

Exclusion Criteria:

• Diagnosis of intellectual deficiency according to DSM 5 criteria
• Drug prescribed for somatic condition that could influence cerebral functioning

Related Conditions & MeSH terms

• 22q11.2 Deletion Syndrome
• Craniosynostoses
• DiGeorge Syndrome
• Marfan Syndrome
• Syndrome

Intervention

Behavioral:
• Magnitude comparison tasks and neuropsychological testing
neuropsychological testing (ZAREKI-R) and magnitude comparison tasks with stimuli of different types (visual, visuo-spatial)

Locations

Country	Name	City	State
France	Hopital Vinatier	Lyon	Rhone Alpes

Sponsors (1)

Lead Sponsor	Collaborator
Hôpital le Vinatier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of impaired scaled score	percentage of impaired scaled score at ZAREKI-R	single day
Secondary	Percentage of correct responses	percentage of correct responses in magnitude comparisons tasks	single day
Secondary	Mean reaction time	mean reaction time in magnitude comparison tasks	single day